10.1038/s41598-020-75621-5 Summary Keywords incretinbased therapy, GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), T2D (type 2 diabetes), obesity, incretin receptors Citation Austin GO and Tomas A (2023) Variation in responses to incretin therapy: Modifiable and non-modifiable factors
Broad-Use Case Standouts : Yaoling Biotechnology (Guangzhou) Co., Ltd
However, many patients remain undiagnosed and untreated, largely due to challenges in testing and treatment [7, 8]
Yuan LQ, Lu Y, Luo XH, Xie H, Wu XP, Liao EY
This compound is not approved as a drug, diagnostic, or dietary ingredient, and is not manufactured, packaged, or marketed for human consumption, self-experimentation, clinical application, or any use outside properly designed and ethically approved research protocols.
Regular monitoring and proactive management can prevent minor side effects from becoming major issues